Home Gilead Expands Hepatitis C Generic Licensing Agreements to Include...
 

Keywords :   


Gilead Expands Hepatitis C Generic Licensing Agreements to Include...

2015-01-26 12:49:40| Biotech - Topix.net

FOSTER CITY, Calif.-- -- Gilead Sciences, Inc. today announced that the company has expanded its hepatitis C generic licensing agreements to include the investigational NS5A inhibitor GS-5816, which is being evaluated in Phase 3 clinical studies as part of a single tablet regimen that combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis C. The expanded agreements will allow Gilead's India-based partners to manufacture GS-5816 and the single tablet regimen of sofosbuvir/GS-5816, once approved, for distribution in 91 developing countries, which together account for 54 percent of the total worldwide population of individuals infected with the hepatitis C virus .

Tags: include generic licensing agreements

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Graphics
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
More »